Mast Therapeutics (NYSEMKT:MSTX) has been rated by 3 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $5 and the lowest price target forecast is $1. The average forecast of all the analysts is $2.67 and the expected standard deviation is $2.08.
Shares of Mast Therapeutics, Inc. rose by 2.17% in the last five trading days and 14.63% for the last 4 weeks. Mast Therapeutics, Inc. is up 74.07% in the last 3-month period. Year-to-Date the stock performance stands at 11.9%.
Mast Therapeutics (NYSEMKT:MSTX) : 4 brokerage houses believe that Mast Therapeutics (NYSEMKT:MSTX) is a Strong Buy at current levels. Zacks Investment Research suggests a Buy with a rank of 2.The median of all the 4 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.
Mast Therapeutics (NYSEMKT:MSTX): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $0.47 and $0.36 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $0.47. The buying momentum continued till the end and the stock did not give up its gains. It closed at $0.47, notching a gain of 2.17% for the day. The total traded volume was 6,736,364 . The stock had closed at $0.46 on the previous day.
In an insider trading activity, Roberts Brandi, CFO of Mast Therapeutics, Inc., executed a transaction worth $19,000 on March 26, 2015. A total of 38,000 shares were purchased at an average price of $0.5. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Mast Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops therapies for serious or life-threatening diseases with unmet needs. The Company leverages its Molecular Adhesion and Sealant Technology (MAST) platform, to develop MST-188 (vepoloxamer) Injection, the Companys lead product candidate. Vepoloxamer is being tested in a Phase III clinical study called EPIC for the treatment of vaso-occlusive crisis in patients with sickle cell disease. The Company also develops AIR001, a sodium nitrite solution for intermittent inhalation through nebulizer. AIR001 is being tested in multiple institution-sponsored Phase IIa clinical studies that provide the Company with data on AIR001s potential to treat patients with preserved ejection fraction (HFpEF).